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OBJECTIVE: Technology advances have introduced many novel
oncology drugs to the market recently. Economic models com-
paring chemotherapy drugs often assumed similar treatment
pattern (e.g., same duration in best supportive care (BSC)) fol-
lowing the completion/discontinuity of chemotherapy. This study
explores the association between technology advances and treat-
ment patterns by examining utilization patterns among Medicare
beneﬁciaries with metastatic colorectal cancer (MCRC) when a
new technology irinotecan (CPT-11) became available in 1999.
METHODS: A sample of chemo-treated MCRC patients diag-
nosed after January 1, 1998 and died before December 31, 2001
was selected from the SEER-Medicare data. A multivariate logis-
tic model was used to examine factors associated with receiving
CPT-11. The course of cancer treatment was categorized as pre-
chemotherapy, chemotherapy, and post-chemotherapy (i.e., BSC)
stages. T-test was used to compare the duration at each stage for
patients who received CPT-11 vs. those who did not. RESULTS:
The study sample included 627 chemo-treated MCRC patients.
Among patients with identiﬁable chemotherapy regimens (N =
477), 45.6% had at least one claim indicative of CPT11 (J9206).
The logistic model showed that compared with patients in the
age group 65–69, those in the age group 75–79 (OR = 0.42; P
= 0.008) and > = 80 (OR = 0.33; P = 0.001) were signiﬁcantly
less likely to receive CPT-11. No gender (OR = 1.36; P = 0.13)
or racial difference (OR = 1.1; P = 0.76) was found. Compared
with the non-users, the CPT-11 group had longer survival (547
vs. 359 days, P < 0.0001), longer time on chemotherapy (398 
vs. 164; P < 0.0001) and shorter time in BSC (75 vs. 122; P =
0.0006). No difference was found in the pre-chemo duration (73
vs. 70; P = 0.86). CONCLUSIONS: New technology appears to
have changed the time allocation in different treatment stages in
cancer; it lengthens the duration of chemotherapy and shortens
that of BSC. The observed survival difference in this study needs
to be interpreted with caution as it may be subject to sample
selection bias.
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OBJECTIVES: There has been no comprehensive analysis of
phase I cancer trials since 1991, despite the transition from cyto-
toxic to targeted drugs. Trends in response rates (RR) and toxic
death rates (TDR) for modern phase I trials are therefore
unknown. We set out to perform the most extensive outcomes
analysis to date of phase I cancer trials. METHODS: We ana-
lyzed the composition and outcomes of all phase I cancer trials
submitted to meeting of the American Society of Clinical
Oncoloy for years 1991 through 2002. For trials testing unap-
proved, single-agents in solid tumors, we reviewed published
reports and performed patient-level analysis. The major out-
comes variables included overall response rate (RR) and toxic
death rate (TDR). We also analyzed the use of biomarkers (BM)
and surrogate endpoints (SE). RESULTS: The overall data set
included 2439 trials. Over the period of analysis, phase I trials
have become signiﬁcantly more international, more complex in
design, and more likely to identify a commercial sponsor. Drugs
under investigation have become more likely to be given by the
oral route, less likely to be produced by recombinant technol-
ogy, and less likely to be cytotoxic. The strongest predictor for
inclusion of a BM or SE was NIH sponsorship (odds ratio, 2.9).
The overall RR and TDR for single-agent studies published in
ﬁnal form was 3.96% and 0.6%, respectively. Both RR and TDR
fell signiﬁcantly over the period. In linear regression models, RR
fell from 8.0% in 1991 to 2.4% in 2001; but the fall in TDR
was more pronounced over the same period. Signiﬁcantly higher
RRs and TDRs were seen among cytotoxic drugs as compared
to targeted and biologic agents. CONCLUSIONS: The compo-
sition and design of phase I cancer trials is changing. Although
overall RRs have declined, the risk/beneﬁt ratio for patients may
be improving.
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OBJECTIVE: The use of imatinib mesylate as ﬁrst line treatment
in management of chronic phase chronic myeloid leukemia
(CML) is controversial. The objective of this study was to
examine signiﬁcant inﬂuences on physician recommendation for
imatinib mesylate in chronic phase CML patients. METHODS:
Data were collected via e-mail and web-based survey from a
random sample of 1100 hematologists/oncologists listed in 
the American Society of Clinical Oncology (ASCO) database.
Rogers’ model of adoption of innovations was used as the main
framework for the study. A series of pre-tested vignettes varying
patient age and disease severity were used to assess physician rec-
ommendations to treat with imatinib vs. bone marrow trans-
plant. A visual analog scale was used to measure physicians’
recommendations. The main survey procedure used a modiﬁed
Dillman’s method. Factor analysis was performed for appropri-
ate measures. Multiple regression analysis was used to test the
model. Based on the theoretical model, the categories of inde-
pendent variables included: innovation characteristics, commu-
nication channels, physician characteristics, social system
characteristics and control variables. A within subjects repeated
measures analysis was conducted to study the inﬂuence of pa-
tient age and disease severity on physician recommendation.
RESULTS: A total of 305 responses were received giving a
response rate of 29%. The regression model was found to be sig-
niﬁcant (p < 0.05). Perceived relative advantage of imatinib in
efﬁcacy, peer inﬂuence, past experience and academic afﬁliation
were found to be signiﬁcant positive inﬂuences. Specialty in bone
marrow transplantation was found to be a signiﬁcant negative
inﬂuence. Physicians were found to recommend imatinib mesy-
late to a greater extent in patients at least 55 years old as com-
pared to younger ones. CONCLUSION: Rogers’ model of
adoption of innovation is useful in explaining physician recom-
mendation for imatinib mesylate. In addition, patient age is a
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OBJECTIVES: Clinical trials suggest that chemotherapy offers a
modest survival advantage in advanced nonsmall cell lung cancer
